Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Pneumonia I: Introduction

Pneumonia I: Introduction

Pneumonia is an infection of the lower respiratory tract that leads to inflammation of the lung parenchyma, often resulting in the accumulation of inflammatory exudate in the alveoli and airways. Unlike the watery, low-protein fluid exudate in pulmonary edema, the exudate in this case is a thick fluid rich in immune cells, proteins, and debris produced during infection and inflammation.This impairs gas exchange and can lead to consolidation of lung tissue. The infection may be caused by a...

Pneumonia I: Introduction

Pneumonia I: Introduction

Pneumonia is an acute respiratory infection that targets the lungs, specifically the alveoli. These tiny air sacs, essential for oxygen exchange, become engorged with pus and fluid, severely hindering breathing, decreasing oxygen absorption, and causing significant pain and discomfort during respiration.
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...

Atypical Pneumonia

Atypical Pneumonia

Atypical pneumonia, often caused by Mycoplasma pneumoniae, is a form of pulmonary infection that differs from the classical presentation of bacterial pneumonia in both its cause and clinical symptoms. Mycoplasma pneumoniae is a pleomorphic bacterium notable for its lack of a rigid cell wall. This structural characteristic imparts resistance to beta-lactam antibiotics and significantly influences the bacterium’s behavior within the human host.Other pathogens responsible for the disease include...

Pneumonia III: Complications and Assessment

Pneumonia III: Complications and Assessment

Pneumonia poses the potential for numerous complications that warrant consideration. These complications include the following:

Pneumonia II: Pathophysiology

Pneumonia II: Pathophysiology

The pathophysiology of pneumonia involves the following steps:

Pneumonia V: Nursing management and Prevention

Pneumonia V: Nursing management and Prevention

Nursing management of pneumonia involves promoting airway patency, facilitating rest and conserving energy, encouraging fluid intake, maintaining nutrition, and educating patients.
The nurse must practice strict medical asepsis and adhere to infection control guidelines to minimize healthcare-associated infections.
Enhance airway patency
Position the patient correctly to facilitate drainage of the affected lung segments. Manual or mechanical percussion and vibration can also be employed.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Anti-Methicillin-Resistant Staphylococcus aureus (MRSA) Cephalosporins Plus Daptomycin as Initial Therapy for MRSA Bacteremia: Does a "Hit Hard and Fast" Strategy Improve Outcomes?

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·2026

Same author

Predictors of mortality and therapeutic efficacy in carbapenem-resistant Acinetobacter baumannii bacteremia.

The Journal of infection·2026

Same author

Hemodialysis Central Venous Catheter-Associated Bloodstream Infection Caused by <i>Stenotrophomonas maltophilia</i> Treated with Cefiderocol and Levofloxacin After Failure of Trimethoprim-Sulfamethoxazole Monotherapy and Device Replacement.

Antibiotics (Basel, Switzerland)·2026

Same author

Sex disparities in tuberculosis outcomes: evidence from a multicenter Italian cohort (Italian South TB Network (ISTB-Net).

Infection·2026

Same author

Corrigendum to "Team-based, hybrid, or standard of care? Organizational models of tuberculosis care on tuberculosis outcomes in eleven Italian hospital" [Clin Microbiol Infect (2025) 31(12) 2033-2040].

Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases·2025

Same author

Reply to Comment on "Why do echinocandins fail? Identifying key predictors to improve clinical outcomes of Candida bloodstream infections: A retrospective multicenter cohort study".

International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases·2025

Search research articles

Related Experiment Video

Updated: Jun 23, 2026

Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria

Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria

Published on: February 23, 2014

Community-acquired pneumonia.

Sergio Carbonara, Laura Monno, Benedetta Longo

Current Opinion in Pulmonary Medicine

|April 24, 2009

Summary

Recent advances refine community-acquired pneumonia (CAP) management, improving outcomes. Further research is needed to address ongoing debates in diagnosis, treatment, and patient care for this significant disease.

Area of Science:

Pulmonology
Infectious Diseases
Critical Care Medicine

Background:

Community-acquired pneumonia (CAP) remains a significant cause of illness, death, and healthcare costs.
Adherence to CAP management guidelines improves clinical outcomes.
Several aspects of CAP diagnosis and treatment require further clarification.

Discussion:

New tools enhance CAP severity assessment, but practical clinical rules are needed.
Debates persist regarding empirical antimicrobial therapy, including atypical coverage and fluoroquinolone use.
Novel antibiotics like tigecycline and cethromycin show promise, alongside enhanced amoxicillin/clavulanate for resistant strains.

Key Insights:

Rigid time-to-antibiotic rules are inappropriate; shorter treatments benefit non-severe patients.

More Related Videos

Long Term Chronic Pseudomonas aeruginosa Airway Infection in Mice

Long Term Chronic Pseudomonas aeruginosa Airway Infection in Mice

Published on: March 17, 2014

Related Experiment Videos

Last Updated: Jun 23, 2026

Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria

Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria

Published on: February 23, 2014

Long Term Chronic Pseudomonas aeruginosa Airway Infection in Mice

Long Term Chronic Pseudomonas aeruginosa Airway Infection in Mice

Published on: March 17, 2014

Acute myocardial infarction requires special attention in severe CAP or treatment failure.

Optimizing CAP management necessitates addressing current uncertainties.

Outlook:

Future research should focus on defining optimal severity assessment tools and antimicrobial strategies.
Further investigation into new antimicrobial agents and treatment durations is crucial.
Addressing unresolved issues in CAP management will optimize patient outcomes and reduce healthcare burden.